We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aridis Pharmaceuticals, Inc. (ARDS - Free Report) announced that its investigational dual antibody, COVID-19 mAb cocktail therapy, AR-712, effectively binds and neutralizes the Delta variant of the virus. The candidate is being developed as a self-administered, at-home inhaled treatment for COVID-19 patients who are not yet hospitalized.
Per the company, a binding analysis proposes that AR-712 will be effective against all Variants of Interest and Variants of Concern as outlined by the U.S. Centers for Disease Control and Prevention.
Shares of Aridis Pharmaceuticals were up 5.2% in after-hours trading on Monday following announcement of the news. In fact, the stock has rallied 20.2% so far this year against the industry’s decrease of 1.7%.
Image Source: Zacks Investment Research
Per the U.S. Centers for Disease Control and Prevention, the Delta variant has become the most dominant strain in the United States, accounting for the majority of new COVID-19 cases in the country. The World Health Organization has warned that Delta will become the globally dominant variant of the coronavirus in the coming months.
Notably, the inhaled dual antibody cocktail, AR-712, is expected to provide broad coverage of all known high-risk variants. In preclinical studies supported by NIAID, AR-712 has demonstrated strong therapeutic efficacy of inhaled delivery in a SARS-CoV-2 hamster challenge model.
Aridis Pharmaceuticals expects to begin clinical studies on AR-712 in the second half of 2021. The company is presently focused on finalizing the design of a phase I/II/III study on the candidate.
AR-712, which is being developed to treat non-hospitalized mild to moderate COVID-19 patients by inhalation, is expected to substantially lower the barrier in treating COVID-19 patients and encourage treatment much earlier at their own homes.
AR-712 is a cocktail of two fully human IgG1 mAbs – AR-711 and AR-713 – that are directed against the receptor-binding domain of the COVID-19 virus.
We remind investors that the FDA has granted an Emergency Use Authorization (“EUA”) to Regeneron’s (REGN - Free Report) antibody cocktail, REGEN-COV (casirivimab and imdevimab), for treating mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing ≥40 kg) and those who are at high risk of progressing to severe COVID-19, including hospitalization or death.
The agency has also issued an EUA to Eli Lilly’s (LLY - Free Report) antibody cocktail, bamlanivimab plus etesevimab, which can be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients. The FDA has also granted an EUA to Vir Biotechnology (VIR - Free Report) and GlaxoSmithKline’s monoclonal antibody, sotrovimab, for the treatment of mild to moderate COVID-19 in adults and pediatric patients.
Image: Bigstock
Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant
Aridis Pharmaceuticals, Inc. (ARDS - Free Report) announced that its investigational dual antibody, COVID-19 mAb cocktail therapy, AR-712, effectively binds and neutralizes the Delta variant of the virus. The candidate is being developed as a self-administered, at-home inhaled treatment for COVID-19 patients who are not yet hospitalized.
Per the company, a binding analysis proposes that AR-712 will be effective against all Variants of Interest and Variants of Concern as outlined by the U.S. Centers for Disease Control and Prevention.
Shares of Aridis Pharmaceuticals were up 5.2% in after-hours trading on Monday following announcement of the news. In fact, the stock has rallied 20.2% so far this year against the industry’s decrease of 1.7%.
Image Source: Zacks Investment Research
Per the U.S. Centers for Disease Control and Prevention, the Delta variant has become the most dominant strain in the United States, accounting for the majority of new COVID-19 cases in the country. The World Health Organization has warned that Delta will become the globally dominant variant of the coronavirus in the coming months.
Notably, the inhaled dual antibody cocktail, AR-712, is expected to provide broad coverage of all known high-risk variants. In preclinical studies supported by NIAID, AR-712 has demonstrated strong therapeutic efficacy of inhaled delivery in a SARS-CoV-2 hamster challenge model.
Aridis Pharmaceuticals expects to begin clinical studies on AR-712 in the second half of 2021. The company is presently focused on finalizing the design of a phase I/II/III study on the candidate.
AR-712, which is being developed to treat non-hospitalized mild to moderate COVID-19 patients by inhalation, is expected to substantially lower the barrier in treating COVID-19 patients and encourage treatment much earlier at their own homes.
AR-712 is a cocktail of two fully human IgG1 mAbs – AR-711 and AR-713 – that are directed against the receptor-binding domain of the COVID-19 virus.
We remind investors that the FDA has granted an Emergency Use Authorization (“EUA”) to Regeneron’s (REGN - Free Report) antibody cocktail, REGEN-COV (casirivimab and imdevimab), for treating mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing ≥40 kg) and those who are at high risk of progressing to severe COVID-19, including hospitalization or death.
The agency has also issued an EUA to Eli Lilly’s (LLY - Free Report) antibody cocktail, bamlanivimab plus etesevimab, which can be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients. The FDA has also granted an EUA to Vir Biotechnology (VIR - Free Report) and GlaxoSmithKline’s monoclonal antibody, sotrovimab, for the treatment of mild to moderate COVID-19 in adults and pediatric patients.
Zacks Rank
Aridis Pharmaceuticals currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.